Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 458 Download: 16 Crossref: 1

Editorial

Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):658-661. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0155

View: 606 Download: 39 Crossref: 2

Original Article

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1103 Download: 100 Crossref: 1

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li

Clin Mol Hepatol. 2025;31(1):147-165. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0478

View: 3754 Download: 573 Web of Science: 2 Crossref: 3

Correspondence

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply

Hyeyeon Hong, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):272-273. Published online February 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0123

View: 2623 Download: 86 Web of Science: 1 Crossref: 1

Original Article

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi

Clin Mol Hepatol. 2024;30(1):49-63. Published online November 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0328

View: 3951 Download: 254 Web of Science: 10 Crossref: 10

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 9791 Download: 451 Web of Science: 30 Crossref: 33

Review

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi

Clin Mol Hepatol. 2022;28(4):773-789. Published online August 8, 2022

DOI: https://doi.org/10.3350/cmh.2021.0383

View: 6857 Download: 266 Web of Science: 40 Crossref: 44

Letter to the Editor

Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei

Clin Mol Hepatol. 2022;28(2):265-266. Published online January 4, 2022

DOI: https://doi.org/10.3350/cmh.2021.0412

View: 7543 Download: 45 Web of Science: 1 Crossref: 1

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 6744 Download: 304 Web of Science: 34 Crossref: 33

Editorial

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 5441 Download: 125 Web of Science: 6 Crossref: 6

Review

Recent advances in nonalcoholic fatty liver disease metabolomics

Hwi Young Kim

Clin Mol Hepatol. 2021;27(4):553-559. Published online June 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0127

View: 12630 Download: 528 Web of Science: 50 Crossref: 50

Original Article

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients

Hee Jae Jung, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim

Clin Mol Hepatol. 2014;20(1):38-46. Published online March 26, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.1.38

View: 9782 Download: 86 Web of Science: 32 Crossref: 31

5

Drug Induced Hepatitis Mimicking Alcoholic Hepatitis

Dae-Young Kang, M.D. and So-Young Jin, M.D.

Clin Mol Hepatol. 2006;12(4):574-578. Published online January 1, 1970

View: 2817 Download: 21

3

Lipid Peroxidation in Chronic Liver Diseases Type B

Kyung Chul Kim , Kwan Sik Lee , Kwang Hyub Han , Won Choi , Chae Yoon Chon , Sang In Lee , Young Myung Moon , Jin Kyung Kang , In Suh Park , Hye Young Kim

Clin Mol Hepatol. 1997;3(1):40-49.

View: 2695 Download: 18

Original Article

Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure

Neha Sharma, Sushmita Pandey, Gaurav Tripathi, Manisha Yadav, Nupur Sharma, Babu Mathew, Abhishak Gupta, Vasundhra Bindal, Sadam H. Bhat, Yash magar, Rimsha Saif, Sanju Yadav, Amritpal Kaur, Rakhi Maiwall, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras

Received July 12, 2024 Accepted December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0554 [Accepted]

View: 2728 Download: 111

CD36 Promotes Iron Accumulation and Dysfunction in CD8⁺ T Cells via the p38-CEBPB-TfR1 Axis in Early-stage Hepatocellular Carcinoma

Yifei Qin, Fei Huo, Zhuan Feng, Jialu Hou, Yaxin Ding, Quancheng Wang, Yu Gui, Ziwei Yang, Jiali Yang, Gang Zhou, Ling Li, Jianli Jiang, Lingmin Kong, Shijie Wang, Gang Nan, Dingqiao Xu, Xiaohang Xie, Lijuan Wang, Qian He, Ruibin Yang, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu

Received November 3, 2024 Accepted March 1, 2025

DOI: https://doi.org/10.3350/cmh.2024.0948 [Accepted]

View: 1084 Download: 206

Correspondence

Correspondence to editorial “Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma”

Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu

Received April 11, 2025 Accepted April 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0402 [Accepted]

View: 223 Download: 15

1 |

Viewed By 10475	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7409	MAFLD: How is it different from NAFLD?
Viewed By 5352	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4780	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4763	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search